Table 1.
Baseline characteristics and data of included studies using PD-1/PD-L1 inhibitors
| Study | Year | Journal | No. | Phase | Intervention | Dose | Mean age (range) | Cancer type | All AE rate (%) | 3–4 AE rate | ORR (%) | 1-year OS rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balar et al13 | 2017 | The Lancet | 119 | phase II | Atezolizumab | 1,200 mg IV q3 weeks | 73 (51–92) | Metastatic/advanced BC | 66 | 16 | 23 | 57 |
| Rosenberg et al14 | 2016 | The Lancet | 310 | phase II | Atezolizumab | 1,200 mg IV q3 weeks | 65 (36–86) | Metastatic/advanced BC | 69 | 16 | 15 | 37 |
| Chen et al15 | 2014 | Nature | 205 | phase I | Atezolizumab | 1,200 mg IV q3 weeks | NR | Metastatic BC | 57.40 | 4.40 | NR | NR |
| Loriot et al16 | 2016 | Annals of Oncology | 310 | phase II | Atezolizumab | 1,200 mg IV q3 weeks | 66.5 (42–86) | Metastatic/advanced BC | 70 | 16 | 16 | NR |
| Powles et al17 | 2014 | Annals of Oncology | 65 | phase I | Atezolizumab | 15 mg/kg IV q3 weeks | 66 (32–91) | Metastatic BC | 57 | 4 | 26 | NR |
| Powles et al18 | 2017 | JAMA Oncology | 191 | phase I/II | Durvalumab | 10 mg/kg IV q2 weeks | 57 (26–82) | Metastatic/advanced BC | 60.70 | 6.80 | 17.80 | 55 |
| Massard et al19 | 2016 | Journal of Clinical Oncology | 61 | phase I/II | Durvalumab | 10 mg/kg IV q2 weeks | 66.0 (34–81) | Advanced BC | 63.90 | 4.90 | 31 | NR |
| Levy et al20 | 2016 | European Journal of Cancer | 23 | phase I/II | Durvalumab | 10 mg/kg IV q2 weeks | 67.0 (34–88) | Metastatic/advanced BC | 50 | 0 | 60 | 44 |
| Sharma et al21 | 2016 | The Lancet Oncology | 78 | phase I/II | Nivolumab | 3 mg/kg IV q2 weeks | 65.5 (31–85) | Metastatic BC | 59 | 22 | 24.40 | 46 |
| Sharma et al22 | 2017 | The Lancet Oncology | 265 | phase II | Nivolumab | 3 mg/kg IV q2 weeks | 66 (38–90) | Metastatic BC | 64 | 18 | 19.60 | NR |
| Bellmunt et al23 | 2017 | The New England Journal of Medicine | 270 | phase III | Pembrolizumab | 200 mg IV q3 weeks | 67 (NR) | Advanced BC | 60.90 | 15 | 21.10 | 43.90 |
| Plimack et al24 | 2017 | The Lancet Oncology | 25 | phase IB | Pembrolizumab | 10 mg/kg IV q2 weeks | 70 (44–85) | Metastatic/advanced BC | 45 | 15 | 26 | 50 |
| Balar et al25 | 2017 | The Lancet Oncology | 265 | phase II | Pembrolizumab | 200 mg IV q3 weeks | 74 (34–94) | Metastatic/advanced BC | 62 | 16 | 24 | NR |
| Apolo et al26 | 2017 | Journal of Clinical Oncology | 37 | phase IB | Avelumab | 10 mg/kg IV q2 weeks | 68 (63–73) | Metastatic BC | 65.90 | 6.80 | 18.20 | 54.30 |
Abbreviations: AE, adverse event; BC, bladder cancer; IV, intravenous; NR, not related; ORR, objective response rate; OS, overall survival.